Cargando…
EE564 Study on the Value Pricing of COVID-19 Vaccine in China Based on the Evidence of Cost-Effectiveness Analysis
Autores principales: | Fu, Y., Zhao, J., Han, P., Yang, L., Ren, T., Zhan, S., Li, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256526/ http://dx.doi.org/10.1016/j.jval.2023.03.2542 |
Ejemplares similares
-
EE19 Cost-Effectiveness Analysis of Nonpharmaceutical Interventions Combined with Inactivated Vaccination and Oral Medicine in China
por: Fu, F., et al.
Publicado: (2023) -
EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023) -
EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England
por: Aballea, S, et al.
Publicado: (2022) -
EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
por: Folorunso, R, et al.
Publicado: (2022) -
564 The Impact of COVID-19 on the Provision of Pediatric Burn Care
por: Chakera, Hawwa, et al.
Publicado: (2022)